Disease
This organism causes leprosy (Hansen’s disease).
Important Properties
M. leprae has not been grown in the laboratory, either on artificial media or in cell culture. It can be grown in experimental animals, such as mice and armadillos. Humans are the natural hosts, although the armadillo appears to be a reservoir for human infection in the Mississippi Delta region where these animals are common. In view of this, leprosy can be thought of as a zoonotic disease, at least in certain southern states, such as Louisiana and Texas.
The optimal temperature for growth (30°C) is lower than body temperature; therefore, M. leprae grows preferentially in the skin and superficial nerves. It grows very slowly, with a doubling time of 14 days. This makes it the slowest-growing human bacterial pathogen. One consequence of this is that antibiotic therapy must be continued for a long time, usually several years.
Lepromatous leprosy in humans is also caused by Mycobacterium lepromatosis, a bacterium found primarily in Mexico and the Caribbean region. This organism also causes lepromatous skin lesions in red squirrels in the British Isles, indicating the probable zoonotic origin of this bacterium.
Transmission
Infection is acquired by prolonged contact with patients with lepromatous leprosy, who discharge M. leprae in large numbers in nasal secretions and from skin lesions. In the United States, leprosy occurs primarily in Texas, Louisiana, California, and Hawaii. Most cases are found in immigrants from Mexico, the Philippines, Southeast Asia, and India. The disease occurs worldwide, with most cases in the tropical areas of Asia and Africa. The armadillo is unlikely to be an important reservoir because it is not found in many areas of the world where leprosy is endemic.
Pathogenesis
The organism replicates intracellularly, typically within skin histiocytes, endothelial cells, and the Schwann cells of nerves. The nerve damage in leprosy is the result of two processes: damage caused by infection with the bacterium and damage caused by CMI attack on the nerves.
There are two distinct forms of leprosy—tuberculoid and lepromatous—with several intermediate forms between the two extremes (Table 1).

Table1. Comparison of Tuberculoid and Lepromatous Leprosy
(1) In tuberculoid (also known as paucibacillary) leprosy, the CMI response to the organism limits its growth, very few acid-fast bacilli are seen, and granulomas containing giant cells form. The nerve damage seems likely to be caused by cell mediated immunity as there are few organisms and the CMI response is strong.
The CMI response consists primarily of CD4-positive cells and a Th-1 profile of cytokines, namely, interferon-γ, interleukin-2, and interleukin-12. It is the CMI response that causes the nerve damage seen in tuberculoid leprosy.
The lepromin skin test result is positive. The lepromin skin test is similar to the tuberculin test (see earlier). An extract of M. leprae is injected intradermally, and induration is observed 48 hours later in those in whom a CMI response against the organism exists.
(2) In lepromatous (also known as multibacillary) leprosy, the cell-mediated response to the organism is poor, the skin and mucous membrane lesions contain large numbers of organ isms, foamy histiocytes rather than granulomas are found, and the lepromin skin test result is negative. The nerve dam age seems likely to be caused by bacterial infection as there are many organisms and the CMI response is poor.
There is evidence that people with lepromatous leprosy produce interferon-β (antiviral interferon) in response to M. leprae infection, whereas people with tuberculoid leprosy produce interferon-γ. Interferon-β inhibits the synthesis of interferon-γ, thereby reducing the CMI response needed to contain the infection.
Note that in lepromatous leprosy, only the cell-mediated response to M. leprae is defective (i.e., the patient is anergic to M. leprae). The cell-mediated response to other organ isms is unaffected, and the humoral response to M. leprae is intact. However, these antibodies are not protective. The T-cell response consists primarily of Th-2 cells.
Clinical Findings
The incubation period averages several years, and the onset of the disease is gradual. In tuberculoid leprosy, hypopigmented macular or plaquelike skin lesions, thickened superficial nerves, and significant anesthesia of the skin lesions occur (Figure 1).

Fig1. Tuberculoid leprosy. The tuberculoid form is characterized by a single, flat, hypopigmented lesion that has lost sensation. (Reproduced with permission from Longo DL, Fauci AS, Kasper DL, et al: Harrison’s Principles of Internal Medicine, 18th ed. New York, NY: McGraw Hill; 2012.)
In lepromatous leprosy, multiple nodular skin lesions occur, resulting in the typical leonine (lionlike) facies. After the onset of therapy, patients with lepromatous leprosy often develop erythema nodosum leprosum (ENL), which is interpreted as a sign that cell-mediated immunity is being restored. ENL is characterized by painful nodules, especially along the extensor surfaces of the tibia and ulna, neuritis, and uveitis.
The disfiguring appearance of the disease results from several factors: (1) the skin anesthesia results in burns and other traumas, which often become infected; (2) resorption of bone leads to loss of features such as the nose and fingertips; and (3) infiltration of the skin and nerves leads to thickening and folding of the skin. In most patients with a single skin lesion, the disease resolves spontaneously. Patients with forms of the disease intermediate between tuberculoid and lepromatous can progress to either extreme.
Patients with untreated lepromatous leprosy living in the Caribbean region may experience diffuse purpuric and ulcerative lesions called Lucio’s phenomenon. These lesions are attributed to immune-complex formation. Secondary infection of the lesions by pyogenic bacteria can cause sepsis and death.
Laboratory Diagnosis
In lepromatous leprosy, the bacilli are easily demonstrated by performing an acid-fast stain of skin lesions or nasal scrapings. Lipid-laden macrophages called “foam cells” containing many acid-fast bacilli are seen in the skin. In the tuberculoid form, very few organisms are seen, and the appearance of typical granulomas is sufficient for diagnosis. Cultures are negative because the organism does not grow on artificial media.
A serologic test for IgM against phenolic glycolipid-1 is useful in the diagnosis of lepromatous leprosy but is not useful in the diagnosis of tuberculoid leprosy. The diagnosis of lepromatous leprosy can be confirmed by using the polymerase chain reaction (PCR) test on a skin sample. False-positive results in the nonspecific serologic tests for syphilis, such as the Venereal Disease Research Laboratory (VDRL) and rapid plasma reagin (RPR) tests, occur frequently in patients with lepromatous leprosy.
Treatment & Prevention
The mainstay of therapy is dapsone (diaminodiphenylsulfone), but because sufficient resistance to the drug has emerged, combination therapy is now recommended. For tuberculoid (paucibacillary) leprosy, dapsone and rifampin are given for 6 to 12 months, whereas for lepromatous (multibacillary) leprosy, a combination of dapsone, rifampin, and clofazimine is given for 12 to 24 months. A combination of ofloxacin plus clarithromycin is an alternative regimen. Thalidomide is the treatment of choice for severe ENL reactions.
Prevention involves isolation of all lepromatous patients, coupled with chemoprophylaxis with dapsone for exposed children. There is no vaccine.